Ferrarotto, R., Kaczmar, J. M., Spigel, D. R., Chung, C. H., Zandberg, D. P., Braña, I., Even, C., Harrington, K. J., Licitra, L. F. L., Keam, B., Rischin, D., Chua, M. L., Reiners, R., Dalal, R., Hanna, G. J. (2026). A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6129